Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2019-01-29

FDA Approved: TREMFYA — Supplemental Application (Janssen Biotech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for TREMFYA (guselkumab) by Janssen Biotech, Inc., resulting in changes to the labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TREMFYA (guselkumab)

Snippet

SUPPL AP for TREMFYA (GUSELKUMAB)